臨牀透析 Vol.19 No.5(11)


特集名 腹膜透析における新しいトレンド
題名 PD+HD併用療法の有効性と問題点
発刊年月 2003年 05月
著者 川西 秀樹 あかね会土谷総合病院
【 要旨 】 透析療法の基本は,透析量と除水量を得ることである.そのため腹膜透析(PD)のみ(血液透析のみ)で十分な透析量や除水量を得ることができなくなったとき,併用療法を考えることが必要となる.適応は透析量不足,除水不全,自己管理不良,貯留液量増加困難(ヘルニア,横隔膜交通症,心不全)などである.また透析量の評価にはequivalent renal urea clearance (EKR) を用いることが有用である.併用療法によりPD療法の欠点が補填され,合併症の克服とQOLの向上が得られる.国際腹膜透析学会(ISPD)委員会では,併用療法を“complimentary dialysis”と呼称することとした.今後,新しい透析療法の形態として定着することが期待される.
Theme New Trends in Peritoneal Dialysis Technologies
Title Present status of combination PD+HD therapy
Author Hideki Kawanishi Akane Foundation Tsuchiya General Hospital
[ Summary ] The fundamental objectives of dialysis are to maintain solute clearance rates and ultrafiltration (UF). If peritoneal dialysis (PD) patients are not maintained at target rates of clearance, they need to increase dialysis dosage but there are limitations on increasing doses of PD only, especially for patients with ultrafiltration failure (UFF). Therefore, combination PD with hemodialysis (HD) (PD+HD) therapy is the simpliest way to resolve this issue. Generally, prescription for PD+HD should be for 5-6 days/week PD and 1 session/week HD. For calculation of PD+HD, we adopt equivalent renal clearance (EKR) and transform to weekly Kt/V and evaluate it as total clearance. The indications for PD+HD are the lack of solute clearance, UFF, bad self-management and other factors including the hernia and diaphragmatic intercourse, as well as severe heart failure, controled by with strict fluid control. PD+HD can resolve the disadvantages of PD and over come complications, leading to higher QOL. It is expected that this will become the standard dialysis modality.
戻る